Lineage Cell Therapeutics Inc (AMEX: LCTX) kicked off on Monday, down -5.90% from the previous trading day, before settling in for the closing price of $1.01. Over the past 52 weeks, LCTX has traded in a range of $0.37-$1.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -2.93% over the last five years. While this was happening, its average annual earnings per share was recorded -9.73%. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
The firm has a total of 77 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.15%, operating margin of -223.1%, and the pretax margin is -169.12%.
Lineage Cell Therapeutics Inc (LCTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 48.58%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -9.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.01% during the next five years compared to -2.93% drop over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Take a look at Lineage Cell Therapeutics Inc’s (LCTX) current performance indicators. Last quarter, stock had a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.05 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Analysing the last 5-days average volume posted by the [Lineage Cell Therapeutics Inc, LCTX], we can find that recorded value of 3.12 million was better than the volume posted last year of 1.99 million. As of the previous 9 days, the stock’s Stochastic %D was 46.71%.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 74.57%, which indicates a significant increase from 43.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.27% in the past 14 days, which was higher than the 87.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6776, while its 200-day Moving Average is $0.6594. Now, the first resistance to watch is $1.0036. This is followed by the second major resistance level at $1.0568. The third major resistance level sits at $1.0936. If the price goes on to break the first support level at $0.9136, it is likely to go to the next support level at $0.8768. Now, if the price goes above the second support level, the third support stands at $0.8236.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
The company with the Market Capitalisation of 217.03 million has total of 228,356K Shares Outstanding. Its annual sales at the moment are 9,500 K in contrast with the sum of -18,610 K annual income. Company’s last quarter sales were recorded 1,500 K and last quarter income was -4,140 K.
